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Abstract
Acyl coenzyme A: isopenicillin N acyltransferase (AT) from Penicillium chrysogenum is an enzyme of interest for the biosynthesis
of -lactam antibiotics. Severe aggregation problems with wild type AT have, however, prevented signiWcant progress in the struc-
ture–function analysis of this enzyme for a decade. In this study, we show an approach to solve this aggregation problem by using
dynamic light scattering (DLS) analysis to probe the aggregation state of the protein in the presence of various additives. After a one-
step puriWcation of recombinant wild type AT with a C-terminal His-tag using Ni2+ aYnity chelate chromatography, addition of a
combination of 5 mM DTT, 250 mM NaCl, and 5 mM EDTA to the puriWed AT eVectively prevented aggregation. In the presence of
these additives, the DLS proWle of AT shows a narrow size distribution indicative of a homogeneous protein solution and the
absence of aggregation. The purity and mono-dispersity of wild type AT was suYcient for the growth of high quality crystals
diVracting to 1.64 Å resolution.
  2005 Elsevier Inc. All rights reserved.
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(AT) from Penicillium chrysogenum catalyzes the con-
version of isopenicillin N (IPN) into penicillin G, which
is the last step in the in vivo biosynthesis of penicillin G
(Fig. 1). This in vivo process is exploited for the commer-
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doi:10.1016/j.pep.2005.02.007cial production of penicillins [1,2]. Starting from penicil-
lin G, obtained from fermentation of P. chrysogenum,
several other -lactam antibiotics can be made via semi-
synthesis [3,4]. In this production process, the side chain
is Wrst removed from the -lactam core, after which the
-lactam nucleus is acylated with the side chain of inter-
est in an enzymatic or non-enzymatic process. Since AT
catalyzes the direct exchange of the side chains, the
enzyme may greatly help to improve the conventional
semi-synthetic penicillin production process by allowing
a one-pot synthesis process [5,6].
To understand how AT catalyzes the exchange of side
chains and to identify the atomic details of how the
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dimensional structure of the enzyme is an indispensable
requirement. Also, insight into the active site from the
three-dimensional structure of AT with its substrates
brings the possibility of the in vivo production of novel
antibiotics closer. Considering that AT shows a rela-
tively wide substrate speciWcity, this structural knowl-
edge may give clues how to design AT enzymes with
altered speciWcity allowing alternative transfer reactions.
AT is produced as a 40 kDa pro-enzyme in P. chrys-
ogenum. This pro-enzyme is processed post-translation-
ally by cleavage of the peptide bond between Gly102 and
Cys103, resulting in - and -subunits of 11 and 29 kDa,
respectively [7,8]. Co-expression of plasmids encoding
the - and -subunits in recombinant Escherichia coli
results in correctly folded active enzyme. In contrast, the
- and -subunits produced separately are insoluble and
inactive, and refolding them separately and mixing them
afterwards does not lead to AT activity. Only refolding
the two subunits together in the presence of urea yields
active enzyme [9]. These in vitro refolding and co-expres-
sion experiments thus indicate that both the - and -
subunits are necessary for proper folding and activity [9].
Site-directed mutagenesis studies on AT have
revealed several interesting mutants that were impaired
in post-translational peptide bond cleavage or/and enzy-
matic activity [10,11]. In particular, mutants of Cys103,
which is one of the residues in the cleavage site, were
devoid of AT activity and remained in the 40 kDa pre-
cursor form [11].
In a previous study, the crystallization and prelimi-
nary X-ray diVraction of one of these mutants,
Cys103Ala, were reported [12]. However, mature wild
type AT could not be crystallized, since it aggregates eas-
ily. Recently, we succeeded in solving the aggregation
problem, making it possible to crystallize wild type AT.Here, we present the cloning, expression, puriWcation,
and successful crystallization of AT as well as our
approach to preventing its aggregation.
Materials and methods
Cloning, expression, and puriWcation of wild type AT
Recombinant E. coli JM109 containing a plasmid,
pHAR11 encoding the penDE gene with a 6-His tag at
the C-terminus, was used in this study. The plasmid
pHAR11 was constructed from pMAT4 [8] (Fig. 2). The
E. coli malE gene from pMAL-c2 (New England Bio-
labs, USA) was ampliWed by PCR using a forward
primer designed with a BamHI site (underlined) [5-tcat
catcatggatccaaaatcgaagaaggtaaa-3] and a reverse
primer including a HindIII site (underlined) after the
malE gene stop codon [5-gtcgtcgtcgtcaagctttcaagtctg
ggcgtctttcag-3]. The obtained fragment was inserted
between the BamHI and HindIII sites of pHAR6 (con-
structed by changing the stop codon sequence of penDE
in pMAT4 into an XbaI site by Kunkel mutagenesis
[13]), resulting in pHAR9 which encodes an out-of-
frame penDE malE fusion. To create the correct reading
frame of the penDE malE fusion, linker oligonucleotides
(sense sequence including part of an XbaI site and a SacI
site (both underlined) [5-ctagatcgagctcgaacaacaacaacaa
taacaataacaacaacg-3] and anti-sense sequence including
part of a BamHI site (underlined) [5-gatccgttgttgttatt
gttattgttgttgttgttcgagctcgat-3]) were inserted between
the XbaI and BamHI sites of pHAR9, resulting in
pHAR10 which is able to express AT-maltose binding
protein fusion protein. Additionally, an oligo cassette
comprising six histidine codons (sense sequence includ-
ing part of an XbaI site and a SacI site (both underlined)Fig. 1. In vivo conversion of IPN to penicillin G in P. chrysogenum.
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anti-sense sequence including part of a HindIII site and
an overhanging BamHI site (underlined) [5-agcttgga
tcctcaatgatggtgatggtggtgcgagctcgat-3]) was inserted
between the XbaI and HindIII sites of pHAR9, resulting
in pHAR11. Cells transformed with pHAR11 were
grown at 28 °C in 2£ YT medium containing 30g/ml
chloramphenicol, and after 2.5 h of cultivation, 0.1 mM
-D-isopropylthiogalactopyranoside (IPTG) was added.
The cells were harvested after overnight growth, and
then resuspended and sonicated in the lysis buVer
(50 mM Tris–HCl, pH 7.5, 8.7%(v/v) glycerol, and
0.1%(v/v) Triton X-100). The sonicated sample was cen-
trifuged (27,138g, 20 min, 4 °C), and the resultant cell-
free extract was applied to an aYnity column (HiTrap
Chelating HP 5 ml, Amersham Biosciences) which had
been loaded with NiSO4 solution and equilibrated with
50 mM Tris–HCl, pH 8.0. After washing away the
unbound protein with equilibration buVer, the protein
was eluted by a step gradient of 50 mM Tris–HCl, pH
8.0, 500 mM NaCl with increasing imidazole concentra-
tion (0, 20, 50, 150, 250, and 500 mM). The puriWed pro-
tein, which was eluted in 50 mM Tris–HCl, pH 8.0,
500 mM NaCl, 250 mM imidazole, was conWrmed bySDS–PAGE, showing two bands of 11 and 29 kDa,
respectively.
Dynamic light scattering analysis
The eVect of additives on the aggregation of wild
type AT was investigated by Dynamic light scattering
(DLS) (DynaPro MSTC161, Protein Solutions, USA).
For DLS analysis, puriWed AT, eluted from the Ni2+
aYnity chelate column, was concentrated and its
buVer exchanged with 50 mM Tris–HCl, pH 8.0,
150 mM NaCl using a Centricon YM-10 concentrator
(Millipore, USA) to a Wnal protein concentration of
3.30 mg/ml. As additives, we used 5 or 10% glycerol, 1
or 5 mM DTT, 1 or 5 mM EDTA, 5 or 10% ethylene
glycol, 1 or 5 mM Tris(2-carboxyethyl)phosphine
(TCEP)–HCl, and 250 or 500 mM NaCl. These addi-
tives, alone and in combination, were added to eluted
protein solution, obtained by the described puriWca-
tion scheme, and incubated at 4 °C for 4, 12, and 33
days. The aggregation state of each sample was evalu-
ated by DLS. Since DLS measures the size distribution
of the protein molecules in the solution, it is sensitive
to variations in particle size and interactions ofFig. 2. Construction of plasmids used in this study. The malE upstream region was linked to the downstream region of penDE for in-frame fusion of
penDE and malE in pHAR10. Plasmid pHAR9 was digested with XbaI and HindIII and an annealed oligo cassette comprising 6 histidine codons was
ligated forming pHAR11. 5SrrnBT1T2 and Cmr indicate a terminator and chloramphenicol-resistance cassette, respectively. M13IG represents the
intergenic sequence in M13.
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aggregation is recognizable by an increase in the
hydrodynamic radius (Rh).
Crystallization of AT
An initial crystallization condition was found using
the Wizard II crystal screen kit (Jena Bioscience, Ger-
many) using the microbatch method under oil [15] and
an Oryx 6 crystallization robot (Douglas Instruments,
UK). Protein solution (1l, 8.28 mg/ml) was mixed with
1 l of reservoir solution containing 2 M phosphate
(0.8 M NaH2PO4/1.2 M K2HPO4) and 0.1 M Na-ace-
tate, pH 6.7. After optimization of this crystallization
condition using the hanging-drop setup [16], crystals
appeared within a week at room temperature in a
mixture of 1.5 l protein solution (9.03 mg/ml) and
1.5 l of reservoir solution containing 1.95 M phos-
phate (0.78 M NaH2PO4/1.17 M K2HPO4) and 25 mM
Na-acetate, pH 6.9.
Table 1
PuriWcation of wild type AT-His6
1.07 g wet cells, corresponding to 140 ml culture, were used for
puriWcation.







Cell free extract 9.06 13 117.8
AYnity chelate 
chromatography
1.79 9 16.1Results and discussion
PuriWcation of wild type AT
PuriWcation steps are summarized in Table 1. Since
wild type AT with a C-terminal His-tag binds tightly to
the Ni2+ aYnity chelate column, the protein could be
puriWed in a single step, using an elution buVer with a
high concentration of imidazole (250 mM). The total
yield of recombinant AT was 115 mg protein/L culture.
Unfortunately, in spite of the fast single-step puriWca-
tion, protein precipitation was observed in the eluate
within several hours after puriWcation. To solve this
severe aggregation problem, we investigated the eVect of
various additives. We did not test AT activity in this
study, since an accurate HPLC AT assay is too time-
consuming to combine with rapid AT puriWcation.
Instead of checking the enzymatic activity of AT, we
conWrmed the maturation to wild type, i.e., the presence
of post-translationally cleaved AT (11 and 29 kDa sub-
units) by SDS–PAGE (See Improved puriWcation and
storage conditions of wild type AT), since this cleavage
has been found previously to be essential for enzyme
activity.
Dynamic light scattering analysis
Fig. 3 shows the results of Dynamic light scattering
(DLS) experiments with the protein after 4 days in the
presence of various additives. Compared to the sample
without additives (50 mM Tris–HCl, pH 8.0, 150 mMFig. 3. EVect of single additives as observed with dynamic light scattering after 4 days of storage of the samples at 4 °C [(1) buVer: AT in 50 mM Tris–
HCl, pH 8.0, 150 mM NaCl; (2) DTT: AT in 50 mM Tris–HCl, pH 8.0, 150 mM NaCl, and 5 mM DTT; (3) EDTA: AT in 50 mM Tris–HCl, pH 8.0,
150 mM NaCl, and 5 mM EDTA; (4) TCEP: AT in 50 mM Tris–HCl, pH 8.0, 150 mM NaCl, and 5 mM TCEP–HCl; and (5) NaCl: AT in 50 mM
Tris–HCl, pH 8.0, 500 mM NaCl]. The peaks at Rh D »4.0 nm correspond to unaggregated AT. The presence of peaks at Rh > 10 nm is indicative of
aggregation. The diVerent colors of each sample are diVerent ‘sets’ of Rh.
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5 mM TCEP–HCl show reduced aggregation (no signal
at Rh higher than 10 nm). With 5 mM DTT, the signal at
Rh D 4.0 becomes narrower, which is an indication that
the particles become more uniform in size, i.e., there are
less interactions between the protein molecules [17].
To optimize the conditions for puriWcation and stor-
age of AT, various combinations of additives were stud-
ied. The results of the DLS measurements are
summarized in Fig. 4. No aggregation is observed after
33 days in the presence of 1 mM TCEP + 250 mM
NaCl + 1 mM EDTA. Although we also tested the eVect
of each single additive after 33 days, none of them on
their own was eVective in preventing aggregation during
this time period (Fig. 4). Addition of 1 mM TCEP shows
broader peaks than the sample without additives
(50 mM Tris–HCl, pH 8.0, 150 mM NaCl), but the inten-
sity of the signal from the latter sample indicates that
most of protein is aggregated. Addition of 1 mM DTT
does not show any eVect. Higher concentrations of the
single additives might be required for long-term storage.In the investigation of combinations of additives, the
substitution of 1 mM TCEP with 1 mM DTT narrows
the peak between 1 and 10 nm (compare graphs 6 and 7
in Fig. 4), although some aggregation remains in another
area (>10 nm). Thus, at least a reducing reagent like
TCEP or DTT is beneWcial for preventing aggregation,
but they are not suYcient for long-term storage of pro-
tein in isolation. TCEP is generally a more eVective
reducing reagent than DTT and more stable without
metal chelators in the buVer, however, in the presence of
a chelating agent, DTT can also be used for long-term
storage of proteins [18]. Because DTT gives a narrower
size distribution of the protein particles in solution, we
prefer the combination of DTT, NaCl, and EDTA as the
additive to prevent the severe aggregation of AT.
Improved puriWcation and storage conditions of wild type 
AT
PuriWed AT, eluted from the Ni2+ aYnity chelate col-
umn according to the procedure described above, wasFig. 4. DLS analyses after 12 days (upper) and 33 days (lower) of storage of the samples at 4 °C, showing the eVect of single additives and the various
combinations of additives [(1) buVer: AT in 50 mM Tris–HCl, pH 8.0, 150 mM NaCl; (2) TCEP: AT in 50 mM Tris–HCl, pH 8.0, 150 mM NaCl, and
1 mM TCEP–HCl; (3) DTT: AT in 50 mM Tris–HCl, pH 8.0, 150 mM NaCl, and 1 mM DTT; (4) TCEP and NaCl: AT in 50 mM Tris–HCl, pH 8.0,
250 mM NaCl, and 1 mM TCEP–HCl; (5) TCEP and EDTA: AT in 50 mM Tris–HCl, pH 8.0, 150 mM NaCl, 1 mM TCEP–HCl, and 1 mM EDTA;
(6) TCEP, NaCl, and EDTA: AT in 50 mM Tris–HCl, pH 8.0, 250 mM NaCl, 1 mM TCEP–HCl, and 1 mM EDTA; and (7) DTT, NaCl, EDTA: AT
in 50 mM Tris–HCl, pH 8.0, 250 mM NaCl, 1 mM DTT, and 1 mM EDTA] in preventing aggregation.
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After concentration of the resulting solution and a
change of buVer to 50 mM Tris–HCl, pH 8.0, 250 mM
NaCl, 5 mM DTT, and 5 mM EDTA using a Centricon
YM-10 concentrator (Millipore, USA), a DLS analysis
was performed. The quality of the puriWed AT was con-
Wrmed by SDS–PAGE and by the DLS proWle (Fig. 5).
No aggregation was observed in the puriWed sample and
the DLS proWle remained mono-disperse and unchanged
after 8 days of storage at ¡80 °C. The puriWed and con-
centrated proteins were divided into smaller volumes,
40l/Eppendorf tube, and stored at ¡80 °C in order to
avoid freeze–thawing of undivided samples.
As a Wnal check of the purity of the enzyme, we set up
protein crystallization experiments with the AT material
prepared according to the Wnal protocol. Good crystals
appeared within a week. They showed excellent diVrac-
tion up to 1.64 Å resolution on beamline ID14-1 (ESRF,
Grenoble, France). The space group of the crystals is C2,
with cell dimensions a D 198.71, b D 68.22, c D 146.96 Å,
D 128.64°. There are four molecules per asymmetric
unit. The cell dimensions diVer from those of the
Cys103Ala mutant AT, thus clearly suggesting a diVer-
ent packing of the molecules in the unit cell. Since the
post-translational peptide bond cleavage can be
expected to give rise to conformational changes, a diVer-
ent packing of the molecules would be in line with such a
conformational diVerence. A full structure determina-
tion of mature wild type AT is currently underway. Pre-
liminary results indicate clear changes around the active
site region of AT as compared to the Cys103Ala mutant.
Conclusion
In this study, a successful puriWcation protocol to
avoid severe protein aggregation was obtained for AT
using DLS analysis to study the eVect of various addi-
tives on protein stability and aggregation. Recombinant
wild type AT with a C-terminal His-tag was puriWed in asingle step using Ni2+ aYnity chelate chromatography.
Incubation of the puriWed AT with a combination of
5 mM DTT + 250 mM NaCl + 5 mM EDTA showed the
eVectiveness of these additives in preventing aggregation
of AT. The DLS proWle remained mono-disperse in the
presence of these additives, which indicates no aggrega-
tion. The quality of puriWed wild type AT was conWrmed
by the successful crystallization of the protein, which
yielded crystals diVracting up to 1.64 Å resolution.
Acknowledgments
This study was supported by the Stichting Technische
Wetenschappen (CW/STW), project No. 790.35.630,
with Wnancial support from the Nederlandse Organisatie
voor Wetenschappelijk Onderzoek (NWO). We thank
the ESRF, Grenoble, for support to carry out the diVrac-
tion experiments.
References
[1] E. Alvarez, J.M. Cantoral, J.L. Barredo, B. Diez, J.F. Martin,
PuriWcation to homogeneity and characterization of acyl coen-
zyme A:6-aminopenicillanic acid acyltransferase of Penicillium
chrysogenum, Antimicrob. Agents Chemother. 31 (1987) 1675–
1682.
[2] R.P. Elander, Industrial production of -lactam antibiotics, Appl.
Microbiol. Biotechnol. 61 (2003) 385–392.
[3] A.L. Demain, R.P. Elander, The -lactam antibiotics: past, pres-
ent, and future, Antonie Van Leeuwenhoek 75 (1999) 5–19.
[4] T.R.M. Barends, H. Yoshida, B.W. Dijkstra, Three-dimensional
structures of enzymes useful for -lactam antibiotic production,
Curr. Opin. Biotechnol. 15 (2004) 356–363.
[5] A.J. Straathof, S. Panke, A. Schmid, The production of Wne chemicals
by biotransformations, Curr. Opin. Biotechnol. 13 (2002) 548–556.
[6] A. Bruggink, A.J. Straathof, L.A. van der Wielen, A ‘Wne’
chemical industry for life science products: green solutions to
chemical challenges, Adv. Biochem. Eng. Biotechnol. 80 (2003)
69–113.
[7] M.B. Tobin, M.D. Fleming, P.L. Skatrud, J.R. Miller, Molecular
characterization of the acyl-coenzyme A:isopenicillin N acyltrans-
ferase gene (penDE) from Penicillium chrysogenum and AspergillusFig. 5. Evaluation of the quality of puriWed AT with additives. (A) The result of SDS–PAGE after addition of DTT and EDTA to AT puriWed by
Ni2+ aYnity chelate chromatography (1, LMW (low molecular weight markers); 2, cell free extract; 3, unbound material from Ni2+ aYnity chelate
column; 4–8, consecutive sample fractions in 50 mM Tris–HCl, pH 8.0, 500 mM NaCl, 250 mM imidazole). (B) The stability of puriWed AT in the
presence of 5 mM DTT + 5 mM EDTA + 250 mM NaCl, as analysed by DLS. (a) PuriWed wild type AT-His (9.03 mg/ml in 50 mM Tris–HCl, pH 8.0,
250 mM NaCl, 5 mM DTT, 5 mM EDTA) (0 day). (b) PuriWed wild type AT-His after 8 days incubation at ¡80 °C.
H. Yoshida et al. / Protein Expression and PuriWcation 41 (2005) 61–67 67nidulans and activity of recombinant enzyme in Escherichia coli, J.
Bacteriol. 172 (1990) 5908–5914.
[8] R.T. Aplin, J.E. Baldwin, P.L. Roach, C.V. Robinson, C.J. Scho-
Weld, Investigations into the post-translational modiWcation and
mechanism of isopenicillin N:acyl-CoA acyltransferase using elec-
trospray mass spectrometry, Biochem. J. 294 (1993) 357–363.
[9] M.B. Tobin, J.E. Baldwin, S.C. Cole, J.R. Miller, P.L. Skatrud,
J.D. Sutherland, The requirement for subunit interaction in the
production of Penicillium chrysogenum acyl-coenzyme A:isopen-
icillin N acyltransferase in Escherichia coli, Gene 132 (1993) 199–
206.
[10] M.B. Tobin, S.C. Cole, S. Kovacevic, J.R. Miller, J.E. Baldwin, J.D.
Sutherland, Acyl-coenzyme A: isopenicillin N acyltransferase
from Penicillium chrysogenum: eVect of amino acid substitutions
at Ser227, Ser230 and Ser309 on proenzyme cleavage and activity,
FEMS Microbiol. Lett. 121 (1994) 39–46.
[11] M.B. Tobin, S.C. Cole, J.R. Miller, J.E. Baldwin, J.D. Suther-
land, Amino-acid substitutions in the cleavage site of acyl-coen-
zyme A:isopenicillin N acyltransferase from Penicillium
chrysogenum: eVect on proenzyme cleavage and activity, Gene
162 (1995) 29–35.[12] C.M.H. Hensgens, E.A. Kroezinga, B.A. van Montfort, J.M. van
der Laan, J.D. Sutherland, B.W. Dijkstra, PuriWcation, crystalliza-
tion and preliminary X-ray diVraction of Cys103Ala acyl coen-
zyme A: isopenicillin N acyltransferase from Penicillium
chrysogenum, Acta Crystallogr. D 58 (2002) 716–718.
[13] T.A. Kunkel, Rapid and eYcient site-speciWc mutagenesis without
phenotypic selection, Proc. Natl. Acad. Sci. USA 82 (1985) 488–492.
[14] S.K. Schmitz, An Introduction to Dynamic Light Scattering by
Macromolecules, Academic Press, New York, 1990.
[15] N.E. Chayen, P.D.S. Stewart, D.M. Blow, Microbatch crystalliza-
tion under oil—a new technique allowing many small-volume
crystallization trials, J. Cryst. Growth 122 (1992) 176–180.
[16] A. McPherson Jr., The growth and preliminary investigation of
protein and nucleic acid crystals for X-ray diVraction analysis,
Methods Biochem. Anal. 23 (1976) 249–345.
[17] M. Zulauf, A. D’Arcy, Light scattering of proteins as a criterion
for crystallization, J. Crystal Growth 122 (1992) 102–106.
[18] E.B. Getz, M. Xiao, T. Chakrabarty, R. Cooke, P.R. Selvin, A
comparison between the sulfhydryl reductants tris(2-carboxy-
ethyl)phosphine and dithiothreitol for use in protein biochemistry,
Anal. Biochem. 273 (1999) 73–80.
